These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 3566246)

  • 1. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents.
    Johnson RC; Kodner C; Russell M
    Antimicrob Agents Chemother; 1987 Feb; 31(2):164-7. PubMed ID: 3566246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents.
    Johnson RC; Kodner CB; Jurkovich PJ; Collins JJ
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2133-6. PubMed ID: 2073103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro and in-vivo susceptibility of Borrelia burgdorferi to azithromycin.
    Johnson RC; Kodner C; Russell M; Girard D
    J Antimicrob Chemother; 1990 Jan; 25 Suppl A():33-8. PubMed ID: 2154436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics.
    Baradaran-Dilmaghani R; Stanek G
    Infection; 1996; 24(1):60-3. PubMed ID: 8852472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo susceptibility of Borrelia burgdorferi.
    Mursic VP; Wilske B; Schierz G; Holmburger M; Süss E
    Eur J Clin Microbiol; 1987 Aug; 6(4):424-6. PubMed ID: 3665899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of Borrelia burgdorferi strains isolated in the Czech Republic.
    Janovská D; Hulínská D; Godová T
    Cent Eur J Public Health; 2001 Feb; 9(1):38-40. PubMed ID: 11243589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro and in-vivo antibiotic susceptibilities of Lyme disease Borrelia isolated in China.
    Li M; Masuzawa T; Wang J; Kawabata M; Yanagihara Y
    J Infect Chemother; 2000 Mar; 6(1):65-7. PubMed ID: 11810535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of the Lyme disease spirochete to seven antimicrobial agents.
    Johnson SE; Klein GC; Schmid GP; Feeley JC
    Yale J Biol Med; 1984; 57(4):549-53. PubMed ID: 6516457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative antimicrobial activity of the new macrolides against Borrelia burgdorferi.
    Preac-Mursic V; Wilske B; Schierz G; Süss E; Gross B
    Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):651-3. PubMed ID: 2550233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility of European human Borrelia burgdorferi sensu stricto strains to antimicrobial agents.
    Veinović G; Cerar T; Strle F; Lotrič-Furlan S; Maraspin V; Cimperman J; Ružić-Sabljić E
    Int J Antimicrob Agents; 2013 Mar; 41(3):288-91. PubMed ID: 23312603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies.
    Dever LL; Jorgensen JH; Barbour AG
    J Clin Microbiol; 1992 Oct; 30(10):2692-7. PubMed ID: 1400969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European Borrelia burgdorferi isolated from humans and ticks culture conditions and antibiotic susceptibility.
    Preac-Mursic V; Wilske B; Schierz G
    Zentralbl Bakteriol Mikrobiol Hyg A; 1986 Dec; 263(1-2):112-8. PubMed ID: 3577473
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Koetsveld J; Draga ROP; Wagemakers A; Manger A; Oei A; Visser CE; Hovius JW
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo antibiotic susceptibility of Lyme disease Borrelia isolated from the ixodid tick in Japan.
    Fujita H; Yamada K; Kurita T; Masuzawa T; Yanagihara Y
    J Dermatol; 1995 Dec; 22(12):935-8. PubMed ID: 8648001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites.
    Kazragis RJ; Dever LL; Jorgensen JH; Barbour AG
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2632-6. PubMed ID: 8913478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of in vitro activities of tigecycline, doxycycline, and tetracycline against the spirochete Borrelia burgdorferi.
    Ates L; Hanssen-Hübner C; Norris DE; Richter D; Kraiczy P; Hunfeld KP
    Ticks Tick Borne Dis; 2010 Mar; 1(1):30-4. PubMed ID: 21771509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New chemotherapeutic approaches in the treatment of Lyme borreliosis.
    Luft BJ; Volkman DJ; Halperin JJ; Dattwyler RJ
    Ann N Y Acad Sci; 1988; 539():352-61. PubMed ID: 3056203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblasts protect the Lyme disease spirochete, Borrelia burgdorferi, from ceftriaxone in vitro.
    Georgilis K; Peacocke M; Klempner MS
    J Infect Dis; 1992 Aug; 166(2):440-4. PubMed ID: 1634816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Borrelia burgdorferi Group: in-vitro antibiotic sensitivity].
    Henneberg JP; Neubert U
    Orv Hetil; 2002 May; 143(21):1195-8. PubMed ID: 12073540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Lebanon.
    Uwaydah M; Jradeh M; Shihab Z
    J Antimicrob Chemother; 1996 Aug; 38(2):283-6. PubMed ID: 8877543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.